Loading
MRD-negative complete remission means not just no leukaemia visible under the microscope, but none detectable with tests a thousand times more sensitive. It is the goal of modern leukaemia treatment.
Complete remission with undetectable measurable residual disease by flow (10^-4) or molecular methods (10^-5 to 10^-6). Prognostic across AML, ALL, CLL, and myeloma; accepted as a regulatory endpoint in ALL (blinatumomab MRD+ label) and, since FDA ODAC 2024, as an accelerated-approval endpoint in myeloma. Drives transplant decisions (AML), blinatumomab consolidation (ALL), and duration debates (CLL).
Showing the technology this term belongs to: Multiparameter flow cytometry MRD.
E1910 changed the standard of care for adult B-ALL: immunotherapy is now part of front-line consolidation even for patients with no detectable leukaemia, because MRD-negative by flow cytometry does not mean cured. It also demonstrated that a T-cell engager can improve overall survival in a curative setting. Chemotherapy-light or chemotherapy-free regimens built on blinatumomab and inotuzumab are the next step.
Revumenib proved that a transcriptional dependency, rather than a kinase, can be drugged in leukaemia, opening treatment for two genetic subgroups that together cover roughly a third of AML plus most infant ALL. It is now approved and is being combined with venetoclax-azacitidine and intensive chemotherapy in front-line trials. Single-agent remissions are often short without transplant.
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
This paper is the proof-of-concept for a living drug: a single infusion of a patient's own engineered T cells could eradicate leukaemia that had survived chemotherapy, transplant and antibody therapy. It defined cytokine release syndrome and its antidote, tocilizumab, and revealed antigen-loss relapse. It led directly to the first approved gene-modified cell therapy three years later.
Shares clonoSEQ, NGS-based MRD (clonoSEQ and molecular MRD), Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
Shares NPM1 mutation, VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Acute myeloid leukaemia.
Shares clonoSEQ, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia.
Shares PhALLCON, Transplant-free Ph-positive ALL for MRD-negative adults, NGS-based MRD (clonoSEQ and molecular MRD), Multiparameter flow cytometry MRD.
Shares CLL14, CLL13 / GAIA, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares MRD-guided transplant decisions in intermediate-risk AML, NPM1 mutation, Allogeneic stem cell transplantation, Acute myeloid leukaemia.
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Allogeneic stem cell transplantation, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
Shares CLL14, CLL13 / GAIA, Chronic lymphocytic leukaemia.